| Adiponectin quartiles | Short-term follow-up | ||||
---|---|---|---|---|---|---|
 | I - III | IV | Crude | Adjusted* | ||
 | n = 627 | n = 209 | OR | 95% CI | OR | 95% CI |
Death | 10 (1.6) | 2 (1.0) | 0.6 | 0.4-5.7 | 0.4 | 0.1-2.0 |
MI/PCI | 15 (2.4) | 5 (2.4) | 1.0 | 0.4-2.8 | 1.0 | 0.3-2.7 |
Stroke | 20 (3.2) | 11 (5.3) | 1.7 | 0.8-3.6 | 1.5 | 0.7-3.3 |
Renal failure | 33 (5.3) | 22 (10.5) | 2.1 | 1.2-3.7 | 1.4 | 0.7-2.7 |
Re-exploration | 54 (8.6) | 22 (10.5) | 1.2 | 0.7-2.1 | 0.9 | 0.6-1.9 |
Infections | 29 (4.6) | 11 (5.3) | 1.1 | 0.6-2.3 | 1.0 | 0.5-2.1 |
CVD composite | 43 (6.9) | 17 (8.1) | 1.2 | 0.7-2.2 | 1.0 | 0.6-1.9 |
 | Adiponectin quartiles | Long-term follow-up | ||||
 | I - III | IV | Crude | Adjusted ‡ | ||
 | n = 617 | n = 207 | OR | 95% CI | OR | 95% CI |
Death | 13 (2.1) | 17 (8.2) | 4.2 | 2.0-8.7 | 2.9 | 1.3-6.4 |
MI/PCI | 18 (2.9) | 4 (1.9) | 0.7 | 0.2-2.0 | 0.7 | 0.2-2.1 |
Stroke | 8 (1.3) | 5 (2.4) | 1.9 | 0.6-5.8 | 1.4 | 0.4-4.5 |
Infections | 18 (2.9) | 10 (4.8) | 1.7 | 0.8-3.7 | 1.1 | 0.5-2.6 |
CVD composite | 36 (5.8) | 23 (11.1) | 2.0 | 1.2-3.5 | 1.7 | 0.9-3.1 |